Developing and Evaluating a Surveillance System for Alzheimer's Dementia In the United States
在美国开发和评估阿尔茨海默氏痴呆症监测系统
基本信息
- 批准号:10369902
- 负责人:
- 金额:$ 56.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAdvocacyAffectAgeAlgorithmsAlzheimer disease preventionAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer&aposs disease related dementiaAmericanCOVID-19 impactCOVID-19 mortalityCaringCharacteristicsCodeCognitionCognitiveCommunitiesCountyDataData AnalysesDementiaDiagnosisDiagnosticDiagnostic ServicesEligibility DeterminationEthnic OriginEvaluationGeneral PopulationGeographyGoalsGovernmentHealthHealth and Retirement StudyInformation SystemsLinkLong-Term CareLow Income PopulationMeasuresMedicaidMedicalMedicareMedicare claimMedicare/MedicaidMethodologyMonitorNational Institute on AgingNongovernmental OrganizationsOutcomePatientsPersonsPopulationPredictive ValuePrevalencePublic AdvocaciesPublic HealthRaceResearchResearch DesignResearch PersonnelResourcesRetirementSensitivity and SpecificityServicesSexual and Gender MinoritiesSourceStratification FactorsSurveysSystemTimeUnited StatesUpdateWorkage groupbeneficiarycare systemscomorbiditycostdata infrastructurediagnostic valueethnic minorityfight againsthealth disparityhuman old age (65+)improvedinnovationmortalitypaymentpreventracial minorityrural dwellersservice utilizationsexsociodemographicsvalidation studiesweb site
项目摘要
PROJECT SUMMARY/ABSTRACT
Alzheimer's disease and related dementias (ADRD) affect as many as 5.7 million Americans and will cost the
U.S. economy between $379 and $500 billion per year by 2040. Goal 5 of the 2020 update to the National Plan
to Address Alzheimer's, "Improve data to track progress", recognizes the need for increased surveillance of
ADRD. The goal states, "Data and surveillance efforts are paramount to tracking the burden of ADRD … and
assist with understanding health disparities among populations such as racial and ethnic minorities, low-
income populations, rural residents, and sexual and gender minorities." No data or surveillance system
currently exists for ADRD surveillance. However, Medicare and Medicaid data offer a promising source of
information to track ADRD diagnoses. Medicare covers most Americans over the age of 65, and Medicaid
covers long-term care services for people with ADRD. In 2016, the Data Infrastructure Committee of the
National Institute on Aging (NIA) identified "ways to reduce the significant obstacles faced by researchers in
using medical care claims and encounter data" as a primary NIA objective, highlighting the importance and
value of Medicare and Medicaid data. We propose to create a publicly accessible system to (1) track ADRD
diagnoses in Medicare and Medicaid; (2) conduct research to understand the correlation between diagnosed
and assessed dementia; and (3) demonstrate the value of the new system by using its data to evaluate an
important research question. In Aim 1, we propose to leverage an established set of partners and
methodologies to develop a publicly accessible system to monitor and surveil ADRD diagnoses in Medicare
and Medicaid, providing information at the national, state and county level and by age, sex, race/ethnicity,
comorbidity, eligibility and other characteristics and stratification factors. Medical claims do not identify all
persons living with dementia, so additional research is needed to understand the biases embedded in payment
claims information. In Aim 2, we will evaluate the predictive power of Medicare claims in identifying persons
with assessed dementia using linked data from Medicare and the nationally representative Health and
Retirement Study (HRS). Aim 2 will estimate the sensitivity and specificity of Medicare claims in detecting HRS
assessed dementia and explore differences across sociodemographic, health, and cognitive factors. Finally, in
Aim 3, we propose to use the new surveillance platform to perform a demonstration analysis; estimating rates
of COVID-19 mortality among patients diagnosed with ADRD in Medicare. When completed, the system we
describe will provide a much-needed ADRD surveillance system, vastly expanding access to and
understanding of Medicare and Medicaid ADRD information for the research community and general public.
项目总结/摘要
阿尔茨海默病和相关痴呆症(ADRD)影响多达570万美国人,
美国到2040年,经济将达到每年3790亿至5000亿美元。2020年国家计划更新目标5
解决阿尔茨海默氏症,“改善数据跟踪进展”,认识到需要加强监测,
ADRD。该目标指出,“数据和监测工作对于跟踪ADRD的负担至关重要...
帮助了解人口之间的健康差距,如种族和少数民族,低,
收入人口、农村居民以及性和性别少数群体。“没有数据或监视系统
目前,ADRD监测。然而,医疗保险和医疗补助数据提供了一个有希望的来源,
用于跟踪ADRD诊断的信息。医疗保险覆盖了65岁以上的大多数美国人,医疗补助覆盖了65岁以上的大多数美国人。
涵盖ADRD患者的长期护理服务。2016年,数据基础设施委员会
国家老龄化研究所(NIA)确定了“减少研究人员在以下方面面临的重大障碍的方法:
使用医疗保健索赔和遭遇数据”作为NIA的主要目标,强调了
医疗保险和医疗补助数据的价值。我们建议建立一个公开访问的系统,以(1)跟踪ADRD
医疗保险和医疗补助中的诊断;(2)进行研究,以了解诊断之间的相关性
和评估痴呆症;(3)通过使用其数据来评估
重要的研究问题。在目标1中,我们建议利用现有的合作伙伴,
开发一个公众可访问的系统来监测和监督医疗保险中的ADRD诊断的方法
和医疗补助,提供国家,州和县一级的信息,并按年龄,性别,种族/民族,
共患病率、合格性等特征和分层因素。医疗索赔不能确定所有
老年痴呆症患者,因此需要进行更多的研究,以了解支付中的偏见
索赔信息。在目标2中,我们将评估医疗保险索赔在识别人员方面的预测能力
使用来自医疗保险和全国代表性健康和健康的相关数据评估痴呆症,
退休研究(HRS)。目标2将评估医疗保险索赔检测HRS的敏感性和特异性
评估痴呆症并探索社会人口统计学,健康和认知因素的差异。最后在
目标3,我们建议使用新的监测平台进行实证分析;估计发病率
在医疗保险中诊断为ADRD的患者中,COVID-19死亡率。一旦完成,我们
描述将提供一个急需的ADRD监测系统,极大地扩大访问和
为研究界和公众了解Medicare和Medicaid ADRD信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David B Rein其他文献
Place-Based Measures of Inequity and Vision Difficulty and Blindness.
基于地点的不平等以及视力困难和失明的衡量标准。
- DOI:
10.1001/jamaophthalmol.2024.1207 - 发表时间:
2024 - 期刊:
- 影响因子:8.1
- 作者:
Patrice M. Hicks;George Lin;P. Newman;Leslie Niziol;Ming;Maria A. Woodward;A. Elam;D. Musch;Roshanak Mehdipanah;Joshua R Ehrlich;David B Rein - 通讯作者:
David B Rein
Prevalence of Diabetic Retinopathy in Health Care Settings-An Early Warning Sign?
医疗机构中糖尿病视网膜病变的患病率——早期预警信号?
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:8.1
- 作者:
David B Rein;J. Wittenborn - 通讯作者:
J. Wittenborn
David B Rein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David B Rein', 18)}}的其他基金
Developing and Evaluating a Surveillance System for Alzheimer's Dementia In the United States
在美国开发和评估阿尔茨海默氏痴呆症监测系统
- 批准号:
10579989 - 财政年份:2022
- 资助金额:
$ 56.09万 - 项目类别:
Research to Enhance the US Vision and Eye Health Surveillance System
加强美国视力和眼健康监测系统的研究
- 批准号:
10328471 - 财政年份:2019
- 资助金额:
$ 56.09万 - 项目类别:
Establish a Vision and Eye Health Surveillance System for the Nation
建立国家视力和眼睛健康监测系统
- 批准号:
9320018 - 财政年份:2016
- 资助金额:
$ 56.09万 - 项目类别:
Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev
评估跨部门的现实筛查干预措施的成本效益
- 批准号:
8434966 - 财政年份:2009
- 资助金额:
$ 56.09万 - 项目类别:
Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev
评估跨部门的现实筛查干预措施的成本效益
- 批准号:
7658018 - 财政年份:2009
- 资助金额:
$ 56.09万 - 项目类别:
Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev
评估跨部门的现实筛查干预措施的成本效益
- 批准号:
7810575 - 财政年份:2009
- 资助金额:
$ 56.09万 - 项目类别:
Modeling Health Utilization of Medicaid Children
医疗补助儿童的健康利用建模
- 批准号:
6554906 - 财政年份:2002
- 资助金额:
$ 56.09万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 56.09万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 56.09万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 56.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 56.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 56.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)